Combined use of ultra-short acting β-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone

Bibliography

• BRISTOW MR, GINSBURG R, MINOBE W, CUBICEIOTTI RS, SAGEMAN WS: Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N. Engl. J. Med. (1978) 299:1373-1377.
   PubMed Web of Science ®Google Scholar
• LONDON MJ: Perioperative β blockade: facts and controversies. Ann. Card. Anaesth. (2003) 6:117-125.
   PubMedGoogle Scholar
• FERGUSON TB JR, COOMBS LP, PETERSON ED: Society of Thoracic Surgeons National Adult Cardiac Surgery Database Preoperative β-blocker use and mortality and morbidity following CABG surgery in North America. JAMA (2002) 287:2221-2277.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR: β-adrenergic receptor blockade in chronic heart failure. Circulation (2000) 101:558-569.
   PubMed Web of Science ®Google Scholar
• ONG H: β-blockers in hypertension and cardiovascular disease. BMJ (2007) 334:946-949.
   PubMedGoogle Scholar
• WILMSHURST PT, THOMPSON DS, JENKINS BS, COLTART DJ, WEBB-PEPLOE MM: Hemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. Br. Heart J. (1983) 49:49-54.
   Google Scholar
• CORMICAN LJ, DAVIDSON C: Drug review: the evolving role of the cardiac inotrope, enoximone, in heart failure. Br. J. Cardiol. (Acute Interv. Cardiol.) (2002) 9:AIC26-AIC31.
   Google Scholar
• ENDOH M, TERUYUKI Y, TAIRA N, BLINKS J: Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transient in canine ventricular muscle. Circulation (1986) 73 (Suppl. III):117-133.
   Web of Science ®Google Scholar
• SILVER PJ: Biochemical aspects of inhibition of cardiovascular low cyclic adenosine-monophosphate-phosphodiesterase. Am. J. Cardiol. (1989) 63:A2-A8.
   Google Scholar
• COLUCCI WS, WRIGHT RF, BRAUNWALD E: New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. N. Engl. J. Med. (1986) 314:349-358.
   PubMed Web of Science ®Google Scholar
• SKOYLES JR, SHERRY KM: Pharmacology, mechanisms of action and uses of selective phosphodiesterase inhibitors. Br. J. Anaesth. (1992) 68:293-302.
   PubMed Web of Science ®Google Scholar
• HONERJÄGER P, NAWRATH H: Pharmacology of bipyridine phosphodiesterase III inhibitors. Eur. J. Anaesth. (1992) 5:7-146.
   Google Scholar
• KLEIN N, SISKIND S, FRISHMAN W: Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure. Am. J. Cardiol. (1981) 48:170-175.
   PubMed Web of Science ®Google Scholar
• VERNON M, HEEL RC, BRODGEN RN: Enoximone – a review of its pharmacological properties and therapeutic potential. Drugs (1991) 42:997-1017.
   PubMed Web of Science ®Google Scholar
• SUNG RJ, BLANSKI L, KIRSHENBAUM J, MACCOSBE P, TURLAPATY P, LADDU AR: Clinical experience with esmolol, a short-acting β-adrenergic blocker in cardiac arrhythmias and myocardial ischemia. J. Clin. Pharmacol. (1986) 26:A15-A26.
   Google Scholar
• KOVAC AL, MASIONGALE A: Comparison of nicardipine versus esmolol in attenuating the hemodynamic responses to anesthesia emergence and extubation. J. Cardiothorac. Vasc. Anesth. (2007) 21:45-50.
   PubMed Web of Science ®Google Scholar
• CUCCHIARA RF, BENEFIEL DJ, MATTEO RS, DEWOOD M, ALBIN MS: Evaluation of esmolol in controlling increases in heart rate and blood pressure during endotracheal intubation in patients undergoing carotid endarterectomy. Anesthesiology (1986) 65:528-531.
   PubMed Web of Science ®Google Scholar
• MANGANO DT, BROWNER WS, HOLLENBERG M et al.: Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. N. Engl. J. Med. (1990) 323:1781-1788.
   PubMed Web of Science ®Google Scholar
• MANGANO DT, LAYUG EL, WALLACE A, TATEO I: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter study of perioperative ischemia research group. N. Engl. J. Med. (1996) 335:1713-1720.
   PubMed Web of Science ®Google Scholar
• WALLACE A, LAYUG B, TATEO I, LI J; THE MCSPI RESEARCH GROUP: Prophylactic atenolol reduces postoperative myocardial ischemia. Anesthesiology (1998) 88:7-17.
   PubMed Web of Science ®Google Scholar
• POLDERMANS D, BOERSMA E, BAX JJ et al.: The effects of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N. Engl. J. Med. (1999) 341:1789-1794.
   PubMed Web of Science ®Google Scholar
• FLEISHER LA, BECKMAN JA, BROWN KA et al.: ACC/AHA (2006) guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative β-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation (2006) 113:2662-2674.
   PubMed Web of Science ®Google Scholar
• RABY KE, BRUILL SJ, TIMIMI F et al.: The effect of heart rate control on myocardial ischemia among high-risk patients with vascular surgery. Anesth. Analg. (1999) 88:477-482.
   PubMed Web of Science ®Google Scholar
• URBAN MK, MARKOWITZ SM, GORDON MA, URQUHART BL, KLIGFIELD P: Postoperative prophylactic administration of β-adrenergic blockers in patients at risk for myocardial ischemia. Anesth. Analg. (2000) 90:1257-1261.
   PubMed Web of Science ®Google Scholar
• HARWOOD TN, BUTTERWORTH J, PRIELIPP RC et al.: The safety and effectiveness of esmolol in the perioperative period in patients undergoing abdominal aortic surgery. J. Cardiothorac. Vasc. Anesth. (1999) 13:555-561.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT S, BOHM M, ERDMANN E, LOHSE MJ: Analysis of β-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of β 1-adrenergic receptor mRNA in heart failure. J. Am. Coll. Cardiol. (1996) 27:146-154.
   PubMed Web of Science ®Google Scholar
• FOWLER MB, LASER JA, HOPKINS GL et al.: Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation (1986) 74:1290-1302.
   PubMed Web of Science ®Google Scholar
• UNVERFERT DV, BLAUNFORD M, KATES RE, LEIER CV: Tolerance to dobutamine after a 72-hour continuous infusion. Am. J. Med. (1980) 69:262-266.
   PubMed Web of Science ®Google Scholar
• BOLDT J, KLING D, ZICKMANN B, DAPPER F, HEMPELMANN G: Haemodynamic effects of the PDE-inhibitor enoximone in comparison to dobutamine in esmolol-treated cardiac surgery patients. Br. J. Anaesth. (1990) 64:611-616.
   PubMed Web of Science ®Google Scholar
• JANICKI JS, SHROFF SG, WEBER KR: Physiologic response to the inotropic and vasodilator properties of enoximone. Am. J. Cardiol. (1987) 60:C15-C118.
   PubMed Web of Science ®Google Scholar
• SMITH VE, KATZ AM: Inotropic and lusitropic abnormalities as the basis for heart failure. Heart Failure (1988) 3:55-56.
   Google Scholar
• BETHKE T, ESCHENHAGEN T, KLIMKIEWICZ A et al.: Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts. Arzneimittel-Forschung/Drug Res. 41 (1988) 1:437-445.
   Google Scholar
• BAIM DS: Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow. Am. J. Cardiol. (1989) 63:A23-A26.
   Google Scholar
• WEBER KT, GILL SK, JANICKI JS, MASKIN CS, JAIN MC: Newer positive inotropic agents in the treatment of chronic cardiac failure. Drugs (1987) 33:503-519.
   PubMed Web of Science ®Google Scholar
• BENDERSKY R, CHATTERJEE K, PARMLEY WW, BRUNDAGE BH, PORTS TA: Dobutamine in chronic ischemic heart failure: alterations in left ventricular function and coronary hemodynamics. Am. J. Cardiol. (1981) 48:554-556.
   PubMed Web of Science ®Google Scholar
• POP T, TREESE N, CREMER GM, HAEGELE KD, MEYER J: Electrophysiological effects of intravenous MDL 17.043. Int. J. Card. (1986) 12:223-232.
   PubMed Web of Science ®Google Scholar
• ZEPLIN HE, DRANSMANN F: A study of the comparative effects of enoximone and dobutamine on urinary output after open heart surgery. Br. J. Clin. Pract. (1988) 12 (Suppl. 64):65-68.
   Google Scholar
• KERN H, SCHRODER T, KAULFUSS M, MARTIN M, KOX WJ, SPIES CD: Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock patients. Crit. Care Med. (2001) 29:1519-1525.
   PubMed Web of Science ®Google Scholar
• LOICK HM, MOLLHOFF T, BERENDES E, HAMMEL D, VAN AKEN H: Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass. Intensive Care Med. (1997) 23:267-275.
   PubMed Web of Science ®Google Scholar
• BOLDT J, BROSCH C, SUTTNER S, PIPER SN, LEHMANN A, WERLING C: Prophylactic use of the phospodiesterase III inhibitor enoximone in elderly cardiac surgery patients: effect on hemodynamics, inflammation, and markers of organ function. Intensive Care Med. (2002) 28:1462-1469.
   PubMed Web of Science ®Google Scholar
• CARCELES MD, ALEXANDRE F, FUENTE T, LOPEZ-VIDAL J, LAORDEN ML: Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat. Eur. J. Anaesthesiol. (2003) 20:205-211.
   PubMed Web of Science ®Google Scholar
• GALIE N, BRANZI A, MAGNANI G et al.: Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile. Cardiovasc. Drugs. Ther. (1993) 7:337-347.
   PubMed Web of Science ®Google Scholar
• METRA M, NODARI S, D'ALOIA A et al.: β-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J. Am. Coll. Cardiol. (2002) 40:1248-1258.
   PubMed Web of Science ®Google Scholar
• BOLDT J, BROSCH C, LEHMANN A, SUTTNER S, ISGRO F: The prophylactic use of the β-blocker esmolol in combination with phosphodiesterase III inhibitor enoximone in elderly cardiac surgery patients. Anesth. Analg. (2004) 99:1009-1017.
   PubMed Web of Science ®Google Scholar
• CARCELES MD, ALEIXANDRE F, FUENTE T, LOPEZ-VIDAL J, LAORDEN ML: Combined phosphodiesterase inhibition and β-blockade in the GI104313, decreases ischemia-induced arrhythmias in the rat. Can. J. Anaesth. (2001) 48:486-492.
   PubMed Web of Science ®Google Scholar
• ZAUGG M, SCHAUB MC, PASCH T, SPAHN DR: Modulation of β-adrenergic receptor subtype in perioperative medicine: mechanisms and sites of sites of action. Br. J. Anaesth. (2002) 88:101-123.
   PubMed Web of Science ®Google Scholar
• WEI S, CHOW LT, SANDERSON JE: Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J. Am. Coll. Cardiol. (2000) 36:276-281.
   PubMed Web of Science ®Google Scholar
• PORT JD, BRISTOW MR: Altered β-adrenergic receptor gene regulation and signaling in chronic heart failure. J. Mol. Cell. Cardiol. (2001) 33:887-905.
   PubMed Web of Science ®Google Scholar
• SHEPPARD D, DISTEFANO S, BYRD RC et al.: Effects of esmolol on airway function in patients with asthma. J. Clin. Pharmacol. (1986) 26:169-174.
   PubMed Web of Science ®Google Scholar
• ANSELL J, TIARKS C, MCCUE J, PARILLA N, BENOTTI JR: Amrinone-induced thrombocytopenia. Arch. Inter. Med. (1984) 144:949-952.
   PubMedGoogle Scholar
• BOLDT J, KNOTHE CH, ZICKMANN B et al.: Phosphodiesterase-inhibitors enoximone and piroximone in cardiac surgery: influence on platelet count and function. Intensive Care Med. (1992) 18:449-454.
   PubMed Web of Science ®Google Scholar
• SMITH NA, KATES RE, LEBSACK C et al.: Clinical pharmacology of intravenous enoximone: pharmacodynamics and pharmacokinetics in patients with heart failure. Am. Heart J. (1991) 122:755-763.
   PubMed Web of Science ®Google Scholar
• KATZ AM: Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation (1986) 73(Suppl.):III184-III188.
   Web of Science ®Google Scholar
• WITHERING W: An account of the foxglove and some of its medical uses: with practical remarks on dropsy and other diseases. Boehringer Mannheim, Mannheim (1984).
   Google Scholar